Abstract
The initial results of radiation therapy with different chemotherapy treatment regimen are provided in the article. Radiation therapy was carried out in all patients using by linear accelerators in the bremsstrahlung energy mode (6 MeV) once a day, 5 times a week. The single boost dose was 3 Gy, 51 Gy total. Upon reaching total boost dose in 18, 24, 30, 36, 42 and 48 Gy patients of the first and third groups received temozolomide (250 mg). Vincristine was administered intravenously to patients of the second and the fourth groups (1 mg) after reaching the total boost dose 18, 33 and 48 Gy. The next day these patients received nitrosourea derivatives (CCNU 80 mg orally or BCNU 50 mg intravenously). Postoperative chemoradiotherapy with temozolomide in patients with glioblastoma resulted in a significant increase of life expectancy. In GBM/temozolomide group median survival was 16,9 months vs 11,3 months in patients who received vincristine/nitrosourea derivatives (р=0,016). There was no significant difference in life expectancy in patients with AA (р=0,13): median survival was 29,9 (group 3) and 22,7 months (group 4).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
